MACULAR PERFUSION DETERMINED BY FUNDUS FLUORESCEIN ANGIOGRAPHY AT THE 4-MONTH TIME POINT IN A PROSPECTIVE RANDOMIZED TRIAL OF INTRAVITREAL BEVACIZUMAB OR LASER THERAPY IN THE MANAGEMENT OF DIABETIC MACULAR EDEMA (BOLT STUDY)

Abstract

At 4 months, there was no evidence of worsening macular ischemia in either group.